Australia's PBS spend edges up 1% in latest financial year
In Australia, total Pharmaceutical Benefits Scheme (PBS) government expense for the supply of medicines under Section 85 and Section 100 on an accrual accounting basis for the 2018-2019 financial year was A$11,818 million (US$8,193 million), excluding revenue, compared with A$11,690 million for the previous year, an increase of 1.1%.
The majority of the Expenditure and Prescriptions report refers to PBS Section 85 and Section 100 data reported by date of supply financial year, however, a few tables refer to Section 85 only and there are some tables that report pharmacy program expenditure.
Total 2018-19 PBS subsidized prescription volumes increased by 0.5% to a total of 205.1 million, compared to 204.1 million for the 2017-18 financial year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze